- Home
- BRY vs SCPH Comparison
BRY vs SCPH Comparison
Compare BRY & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- SCPH
- Stock Information
- Founded
- BRY 1909
- SCPH 2013
- Country
- BRY United States
- SCPH United States
- Employees
- BRY N/A
- SCPH N/A
- Industry
- BRY Oil & Gas Production
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- BRY Energy
- SCPH Health Care
- Exchange
- BRY Nasdaq
- SCPH Nasdaq
- Market Cap
- BRY 186.1M
- SCPH 173.6M
- IPO Year
- BRY N/A
- SCPH 2017
- Fundamental
- Price
- BRY $3.30
- SCPH $3.84
- Analyst Decision
- BRY Buy
- SCPH Strong Buy
- Analyst Count
- BRY 2
- SCPH 3
- Target Price
- BRY $5.00
- SCPH $14.00
- AVG Volume (30 Days)
- BRY 1.3M
- SCPH 302.2K
- Earning Date
- BRY 08-08-2025
- SCPH 08-13-2025
- Dividend Yield
- BRY 3.64%
- SCPH N/A
- EPS Growth
- BRY N/A
- SCPH N/A
- EPS
- BRY N/A
- SCPH N/A
- Revenue
- BRY $753,737,000.00
- SCPH $41,982,000.00
- Revenue This Year
- BRY N/A
- SCPH $108.95
- Revenue Next Year
- BRY $0.96
- SCPH $73.83
- P/E Ratio
- BRY N/A
- SCPH N/A
- Revenue Growth
- BRY N/A
- SCPH 138.10
- 52 Week Low
- BRY $2.11
- SCPH $1.94
- 52 Week High
- BRY $7.02
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- BRY 70.73
- SCPH 56.83
- Support Level
- BRY $2.99
- SCPH $3.86
- Resistance Level
- BRY $3.39
- SCPH $4.17
- Average True Range (ATR)
- BRY 0.16
- SCPH 0.23
- MACD
- BRY 0.08
- SCPH -0.06
- Stochastic Oscillator
- BRY 90.91
- SCPH 33.33
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.